{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:08:46Z","timestamp":1793646526117,"version":"4.5.1"},"reference-count":39,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:p>Drug development for cancer chemotherapy has an interesting history. A mix of serendipity, animal, cell line, and standard pharmacological principles of dose, dose\u2010response, dose\u2010concentration, dose intensity and combination therapies have been used to develop optimal dosing schedules. However in practice, significant gaps in the translation of preclinical to clinical dosing schedules persist, and clinical development has instead moved to new drug development. A older chemotherapies are still the backbone of most solid tumour schedules, therapeutic drug monitoring has emerged as a method for optimising the dose for individual patients.<\/jats:p>","DOI":"10.1111\/bcp.13979","type":"journal-article","created":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T13:21:50Z","timestamp":1557580910000},"page":"2198-2204","source":"Crossref","is-referenced-by-count":25,"title":["The rationale of dose\u2013response curves in selecting cancer drug dosing"],"prefix":"10.1111","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8614-0199","authenticated-orcid":false,"given":"Jennifer H.","family":"Martin","sequence":"first","affiliation":[{"name":"University of Newcastle. New South Wales  Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0093-4949","authenticated-orcid":false,"given":"Simon","family":"Dimmitt","sequence":"additional","affiliation":[{"name":"University of Newcastle. New South Wales  Australia"},{"name":"University of Western Australia  Crawley Perth Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,6,20]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1946.02870380008004"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9610(63)90232-0"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1941.01210140043004"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM194806032382301"},{"issue":"5","key":"e_1_2_12_6_1","first-page":"1207","article-title":"Growth studies on sarcoma 37 in mice","volume":"16","author":"Goldin A","year":"1956","journal-title":"JNCI J Natl Canc Inst"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197803)41:3<936::AID-CNCR2820410322>3.0.CO;2-B"},{"key":"e_1_2_12_8_1","first-page":"1","article-title":"Experimental evaluation of potential anticancer agents. XII. On the criteria and kinetics associated with \u201ccurability\u201d of experimental leukaemia","volume":"35","author":"Skipper HE","year":"1964","journal-title":"Cancer Chemother Rep"},{"issue":"22","key":"e_1_2_12_9_1","first-page":"6417","article-title":"Preclinical studies and clinical correlation of the effect of alkylating dose","volume":"48","author":"Frei E","year":"1988","journal-title":"Cancer Res"},{"key":"e_1_2_12_10_1","volume-title":"Dose\u2010Response Curves in Clinical Pharmacology","author":"Lemberger L","year":"1989"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197501)35:1<98::AID-CNCR2820350115>3.0.CO;2-B"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl488"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90472-6"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2017.1385680"},{"key":"e_1_2_12_15_1","first-page":"282","article-title":"Increasing therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology","volume":"20","author":"Schabel FN","year":"1984","journal-title":"Pharmacol Therapeut"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004133421501"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.10.202"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1970"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI9872"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2015.09.002"},{"key":"e_1_2_12_21_1","unstructured":"https:\/\/www.smh.com.au\/healthcare\/inquiry\u2010could\u2010not\u2010rule\u2010out\u2010st\u2010vincents\u2010covered\u2010up\u2010chemotherapy\u2010dosing\u2010scandal\u201020170518\u2010gw7rc4.html accessed Jan 10 2019."},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.11.1281"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.8.1162"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.8.2981"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3374"},{"key":"e_1_2_12_26_1","unstructured":"Skipper H.Data and analyses having to do with the influence of dose intensity and duration of treatment (single drugs and combinations) on lethal toxicity and the therapeutic response of experimental neoplasma. Southern Research Institute Birmingham AL booklet1\u201313(1986)."},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20608"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010639201787"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600139"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.9.2590"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-013-9876-7"},{"key":"e_1_2_12_32_1","unstructured":"FernerRE AronsonJK.Susceptibility to adverse drug reactions. BJCP2019."},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.11040"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx339"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199706053362304"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710163371614"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4380-z"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1967.03130200086016"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14020"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.937"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13979","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.13979","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T19:31:07Z","timestamp":1694201467000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,20]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1111\/bcp.13979"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13979","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,20]]}}}